{
    "id": "0903",
    "question": "A 54-year-old man comes to the clinic for management of his gastroesophageal reflux disease (GERD). He is currently on cimetidine for his condition and reports that his GERD initially improved. However, following his recent move to Michigan, he is experiencing more frequent episodes of chest pain (4-5 times a week). The pain is described as burning in quality and is concentrated around his epigastric region following food ingestion. It does not radiate anywhere and is alleviated when he takes antacids. A physical examination demonstrates a healthy male with unremarkable findings. He is subsequently prescribed a new medication for control of his symptoms. What is the most likely mechanism of action of this new medication?",
    "options": {
        "A": "Irreversible inactivation of cyclooxygenase enzyme",
        "B": "Irreversible inhibition of H+/K+-ATPase at parietal cells",
        "C": "Reversible inhibition of H+/K+-ATPase at parietal cells",
        "D": "Reversible inhibition of histamine H2 receptors"
    },
    "answer": "B",
    "predict": "To approach this question, let's break it down step by step: 1. **Understand the patient's condition**: The patient has GERD, which is managed with cimetidine initially, but the symptoms have worsened. He now experiences chest pain (burning, epigastric region) after food ingestion, which is relieved by antacids. 2. **Identify the likely cause of worsening symptoms**: Given the patient's history of GERD and the nature of the chest pain, it's possible that the worsening symptoms are due to an overproduction of stomach acid (hyperacidity), which is not effectively controlled by cimetidine. Cimetidine is an H2-receptor antagonist, which reduces acid production by decreasing histamine release and blocking H2 receptors on parietal cells. 3. **Consider alternative treatments for worsening GERD symptoms**: Given that cimetidine is not effective, the patient may require a different class of medication that can address the underlying cause of hyperacidity. The next step would be to consider medications that can inhibit acid production at the parietal cells. 4. **Evaluate the options**: - **A. Irreversible inactivation of cyclooxygenase enzyme**: This mechanism is associated with nonsteroidal anti-inflammatory drugs (NSAIDs), which are not typically used for GERD management. - **B. Irreversible inhibition of H+/K+-ATPase at parietal cells**: This is the mechanism of action of proton pump inhibitors (PPIs), which are known to be effective in treating GERD by irreversibly inhibiting the H+/K+-ATPase enzyme at the parietal cells, thereby reducing acid production. - **C. Reversible inhibition of H+/K+-ATPase at parietal cells**: This is the mechanism of action of H2-receptor antagonists like cimetidine, which is not effective in this case due to the worsening symptoms. - **D. Reversible inhibition of histamine H2 receptors**: This is also the mechanism of action of H2-receptor antagonists, which, as mentioned, is not effective in this case. **Conclusion**: Given the worsening symptoms of GERD and the need for a medication that can effectively reduce acid production, the most likely mechanism of action of the new medication prescribed for this patient is the irreversible inhibition of H+/K+-ATPase at parietal cells, which is characteristic of proton pump inhibitors (PPIs). ```json {\"step_by_step_thinking\": \"The patient's worsening GERD symptoms after cimetidine suggest a need for a medication that can address the underlying cause of hyperacidity. Given the options, the most likely mechanism of action of the new medication is the irreversible inhibition of H+/K+-ATPase at parietal cells, which is characteristic of proton pump inhibitors (PPIs).\", \"answer_choice\": \"B\"} ```",
    "snippets": [],
    "scores": [],
    "execution_time": 57.244757652282715
}